We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health Drives Drug Affordability by Promoting Competition
Read MoreHide Full Article
Key Takeaways
CVS Caremark is tracking near its historical 90% retention in the PBM selling season.
CVS partnered with Novo Nordisk to expand affordable access to Wegovy.
A new CalPERS contract adds 587,000 members to CVS' PBM from January 2026.
CVS Health (CVS - Free Report) is off to a strong start in the 2026 Pharmacy Benefit Manager (“PBM”) selling season, with Caremark dominating in this highly competitive marketplace. The unit is tracking in line with its historical upper 90% retention rate. Caremark has a long history of driving down prescription and pharmacy costs by increasing competition.
Recently, it partnered with Novo Nordisk to significantly increase access to Wegovy, a GLP-1 drug, for its members at a more affordable price. On July 1, CVS Health took a formulary action to prefer Wegovy, removing Eli Lilly’s weight management drug Zepbound from the Standard Control, Advanced Control and Value formularies. Furthermore, CVS also pairs the medication with its weight management program, where participants have achieved double-digit % weight loss at 12 months, regardless of the drug they use.
Weight management drugs like the GLP-1 can significantly improve health outcomes, but their exorbitant prices often limit access for many. CVS expects its decision could save an estimated 10-15% year over year in the anti-obesity medication space for members using its template formularies.
Last year, Caremark removed Humira from all its major national commercial template formularies, driving the use of Humira biosimilars instead. These alternatives, which have no clinically meaningful difference from their reference product, represent one of the biggest opportunities for reducing drug costs for employers and consumers. The move has already generated more than $1 billion in savings for CVS clients.
Effective Jan. 1, 2026, CVS will begin providing outpatient prescription drug benefits for approximately 587,000 CalPERS members enrolled in Basic or Medicare HMO and PPO plans. The five-year contract emphasizes CVS’ ability to deliver affordable drug benefits and its commitment to performance guarantees in key areas such as managing pharmacy cost trends and ensuring clinical quality.
Latest Developments From CVS Competitors
UnitedHealth Group’s (UNH - Free Report) Optum Rx has raised reimbursement minimums for branded drugs for approximately 2,300 independent pharmacies nationwide, those not affiliated with a pharmacy services administrative organization, chain or other entity. This move, which went into effect on Sept. 1, 2025, will support the long-term sustainability of pharmacies, which play a critical role in patient care.
Amazon (AMZN - Free Report) recently announced the expansion of its third-party logistics product, Amazon Multi-Channel Fulfillment (“MCF”), to support merchants on SHEIN, Shopify and Walmart. By leveraging one shared inventory pool with Fulfillment by Amazon, Amazon MCF empowers businesses to simplify their fulfillment, increase sales through existing channels and quickly launch in new online stores.
CVS Stock Performance, Valuation and Estimates
Year to date, CVS Health shares have surged 67.4% against the industry’s 1% fall.
Image Source: Zacks Investment Research
CVS Health is trading at a forward five-year price/earnings (P/E) of 10.87X, lower than the industry average of 15.05X. The stock has a Value Score of A.
Image Source: Zacks Investment Research
Here’s how analyst estimates for the company’s 2025 and 2026 presently stand.
Image: Bigstock
CVS Health Drives Drug Affordability by Promoting Competition
Key Takeaways
CVS Health (CVS - Free Report) is off to a strong start in the 2026 Pharmacy Benefit Manager (“PBM”) selling season, with Caremark dominating in this highly competitive marketplace. The unit is tracking in line with its historical upper 90% retention rate. Caremark has a long history of driving down prescription and pharmacy costs by increasing competition.
Recently, it partnered with Novo Nordisk to significantly increase access to Wegovy, a GLP-1 drug, for its members at a more affordable price. On July 1, CVS Health took a formulary action to prefer Wegovy, removing Eli Lilly’s weight management drug Zepbound from the Standard Control, Advanced Control and Value formularies. Furthermore, CVS also pairs the medication with its weight management program, where participants have achieved double-digit % weight loss at 12 months, regardless of the drug they use.
Weight management drugs like the GLP-1 can significantly improve health outcomes, but their exorbitant prices often limit access for many. CVS expects its decision could save an estimated 10-15% year over year in the anti-obesity medication space for members using its template formularies.
Last year, Caremark removed Humira from all its major national commercial template formularies, driving the use of Humira biosimilars instead. These alternatives, which have no clinically meaningful difference from their reference product, represent one of the biggest opportunities for reducing drug costs for employers and consumers. The move has already generated more than $1 billion in savings for CVS clients.
Effective Jan. 1, 2026, CVS will begin providing outpatient prescription drug benefits for approximately 587,000 CalPERS members enrolled in Basic or Medicare HMO and PPO plans. The five-year contract emphasizes CVS’ ability to deliver affordable drug benefits and its commitment to performance guarantees in key areas such as managing pharmacy cost trends and ensuring clinical quality.
Latest Developments From CVS Competitors
UnitedHealth Group’s (UNH - Free Report) Optum Rx has raised reimbursement minimums for branded drugs for approximately 2,300 independent pharmacies nationwide, those not affiliated with a pharmacy services administrative organization, chain or other entity. This move, which went into effect on Sept. 1, 2025, will support the long-term sustainability of pharmacies, which play a critical role in patient care.
Amazon (AMZN - Free Report) recently announced the expansion of its third-party logistics product, Amazon Multi-Channel Fulfillment (“MCF”), to support merchants on SHEIN, Shopify and Walmart. By leveraging one shared inventory pool with Fulfillment by Amazon, Amazon MCF empowers businesses to simplify their fulfillment, increase sales through existing channels and quickly launch in new online stores.
CVS Stock Performance, Valuation and Estimates
Year to date, CVS Health shares have surged 67.4% against the industry’s 1% fall.
Image Source: Zacks Investment Research
CVS Health is trading at a forward five-year price/earnings (P/E) of 10.87X, lower than the industry average of 15.05X. The stock has a Value Score of A.
Image Source: Zacks Investment Research
Here’s how analyst estimates for the company’s 2025 and 2026 presently stand.
Image Source: Zacks Investment Research
CVS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.